Eurofins Optimed Clinical Research
and
Spaulding Clinical Research
announced a joint partnership agreement. This partnership leverages the strengths of both companies and facilitates collaboration on integrated clinical services to engage pharmaceutical clients who demand a global footprint.
"The culture of excellence and research facilities designed to execute high-quality studies was very impressive to our team. We felt immediately comfortable with the Optimed clinical team and witnessed their efficient execution of studies," states Daniel Selness, General Manager and Senior Vice President of Operations. "We were very impressed that Spaulding achieved ISO certification, which is not common among US clinical research facilities. Their systems approach with Electronic Data Capture is something that we have been looking to implement, so the partnership will allow us to consider how to collaborate more closely as these systems are put in place," states Yves Donazzolo, MD, CEO and President of Optimed.
Eurofins Optimed and Spaulding Clinical offer a full range of global services to the Pharmaceutical industry and Biotechnology companies from study design through study execution/conduct, data management, statistical analysis, and medical writing. Both companies excel in TQT, first-in-human, multiple rising dose, bioavailability/bioequivalence, drug interaction, food effect studies and Proof-Of-Concept studies in patients.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.